What are the contraindications, precautions, monitoring requirements, and special considerations (including specific populations) for using bevacizumab?

Bevacizumab: Contraindications, Precautions, Monitoring, and Special Considerations

Absolute Contraindications

Bevacizumab must be permanently discontinued in patients who develop Grade 4 hemorrhage, hypertensive crisis, hypertensive encephalopathy, or gastrointestinal perforation. 1, 2, 3

• Squamous cell carcinoma histology in lung cancer is an absolute contraindication due to catastrophic hemoptysis risk, with 5 deaths occurring in early phase 2 studies 4, 5, 4, 2
• Clinically significant hemoptysis (>2.5 mL of blood) excludes bevacizumab use 4, 5, 4
• Recent surgery within 6 weeks or planned elective surgery within 6-8 weeks requires bevacizumab discontinuation due to severe wound healing complications 6, 7, 2, 3, 8
• Extensive prior intra-abdominal surgery increases gastrointestinal perforation risk and contraindicates use 2
• Uncontrolled hypertension (≥180/110 mmHg) requires bevacizumab to be withheld until blood pressure is controlled 1, 5

Relative Contraindications and High-Risk Populations

Bevacizumab should be avoided in patients with ECOG performance status >1, clinically significant cardiovascular disease, or inadequate organ function. 4, 5, 4

• Patients ≥65 years have significantly increased risk of arterial thromboembolic events, particularly stroke 6, 7, 2
• Treated brain metastases are no longer an absolute contraindication, but require no evidence of progression or hemorrhage on imaging within 1 week of treatment, and at least 3 months must have elapsed since neurosurgery 2
• Full-dose anticoagulation is no longer contraindicated, but avoid combining bevacizumab with antiplatelet therapy in patients with end-stage renal disease 2
• Patients with thrombophilia or atrial fibrillation should use tranexamic acid (an antifibrinolytic) with caution, as it represents a relative contraindication 9

Blood Pressure Monitoring and Management

Blood pressure must be measured before every bevacizumab infusion, with a threshold of <160/100 mmHg clinic BP or <150/95 mmHg on ambulatory/home monitoring required to proceed with treatment. 1

Pre-Treatment Assessment

• Baseline blood pressure must be <160/100 mmHg to initiate bevacizumab 1
• If clinic BP ≥160/100 mmHg, arrange ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) before starting therapy 1
• Pre-existing hypertension with BP <160/100 mmHg should not prevent bevacizumab initiation 1

During Treatment Monitoring

• Clinic BP <160/100 mmHg: Continue bevacizumab as scheduled 1
• Clinic BP ≥160/100 mmHg or increase of ≥20/10 mmHg: Omit bevacizumab dose and arrange ABPM/HBPM 1
• Clinic BP ≥180/110 mmHg: Omit bevacizumab dose, initiate or intensify antihypertensive therapy, reassess after ≥2 weeks 1
• Hypertensive crisis: Permanently discontinue bevacizumab and arrange emergency admission 1

Antihypertensive Treatment Algorithm

For antihypertensive-naive patients developing hypertension on bevacizumab, start amlodipine 5 mg daily as first-line therapy. 1

• Step 1: Amlodipine 5 mg daily 1
• Step 2: Add ACE inhibitor (perindopril 2 mg daily) OR ARB (losartan 50 mg daily) 1
• Step 3: Add indapamide 2.5 mg daily 1
• Step 4: Increase dose of ≥1 drug AND/OR add low-dose spironolactone (if K+ <4.5 mmol/L and normal renal function) AND/OR refer to hypertension specialist 1

Post-Treatment Blood Pressure Management

• Hypertension typically resolves after bevacizumab completion, with median resolution time of 87 days (range 3-236 days) 1
• Arrange primary care follow-up within 4 weeks of stopping bevacizumab to reassess need for ongoing antihypertensive therapy 1
• Monitor blood pressure annually once normalized 1

Proteinuria Monitoring

Monitor urine protein every 3-4 weeks during bevacizumab therapy using dipstick testing. 8, 10

• Proteinuria ≥2+ persistent: Discontinue bevacizumab permanently 8
• Overall incidence of all-grade proteinuria is 18% and high-grade proteinuria is 2.4% 11
• Risk of proteinuria increases 5.5-fold compared to controls 11
• Monitor for nephrotic syndrome signs (edema, hypoalbuminemia, hyperlipidemia) 3, 8

Hemorrhage Risk Management

Permanently discontinue bevacizumab for Grade 4 hemorrhage or any life-threatening bleeding event. 2, 3

• Incidence of clinically significant hemoptysis is highest in squamous cell lung cancer (contraindicated) 2, 10
• Monitor for signs of unusual bleeding including coughing or spitting blood 3
• Central nervous system hemorrhage risk is increased in patients with brain metastases 10
• Gastrointestinal bleeding risk is elevated, particularly with concurrent anticoagulation 12, 8

Thromboembolic Event Monitoring

Bevacizumab increases risk of both arterial and venous thromboembolic events, requiring vigilant monitoring and immediate discontinuation for life-threatening events. 3, 8, 10

• Arterial thromboembolic events (stroke, myocardial infarction, transient ischemic attack) occur more frequently in patients ≥65 years 6, 7, 2
• Venous thromboembolism should be managed per American College of Chest Physicians guidelines 8
• Discontinue bevacizumab for new life-threatening arterial or venous thromboembolism 8
• Monitor for signs of stroke, chest pain, shortness of breath, or leg swelling 3

Gastrointestinal Perforation Risk

Monitor for gastrointestinal perforation throughout therapy, with immediate discontinuation required if perforation occurs. 3, 12, 8

• Patients should immediately contact healthcare provider for high fever, rigors, persistent or severe abdominal pain, severe constipation, or vomiting 3
• Risk is highest in patients with extensive prior intra-abdominal surgery 2
• Bowel perforation shares similar pathophysiology with impaired wound healing and bleeding 8
• Permanently discontinue bevacizumab if gastrointestinal perforation develops 3

Surgical Considerations and Wound Healing

Discontinue bevacizumab at least 6 weeks before elective surgery and do not reinitiate until at least 6-8 weeks postoperatively. 6, 7, 2, 3, 8

• Bevacizumab interferes with wound healing through VEGF inhibition 6, 7, 8
• Patients should not undergo surgery without first discussing bevacizumab-related wound healing risks 3
• For emergency surgery, assess risk-benefit ratio carefully given impaired healing potential 8
• Monitor surgical sites closely for dehiscence or delayed healing 8

Specific Populations

Pregnancy and Reproductive Considerations

Bevacizumab causes fetal harm and is contraindicated in pregnancy; females of reproductive potential must use effective contraception during treatment and for 6 months after the last dose. 3

• Advise females to inform healthcare provider of known or suspected pregnancy 3
• Bevacizumab may lead to ovarian failure; discuss fertility preservation options before starting treatment 3
• Do not breastfeed during treatment and for 6 months after the last dose 3

Renal Impairment

• Standard bevacizumab dosing does not require adjustment for renal impairment, but nephrotoxic effects must be considered 2
• Monitor renal function regularly given risk of proteinuria and nephrotic syndrome 3, 8

Elderly Patients

• Patients ≥65 years have increased risk of arterial thromboembolic events, especially stroke 6, 7, 2
• More cautious blood pressure management may be needed, but age alone should not prevent bevacizumab use 1

Hereditary Hemorrhagic Telangiectasia (HHT)

For HHT patients with severe liver vascular malformations, bevacizumab dosing is 5 mg/kg every 2 weeks for 4-6 induction doses, followed by variable maintenance dosing (5 mg/kg every 1-3 months). 9

• Monitor for hypertension, proteinuria, infection, delayed wound healing, and venous thromboembolism 9
• Risk of long-term maintenance therapy is unknown 9
• Bevacizumab's unpredictable efficacy, non-negligible toxicity, and revascularization following withdrawal require careful consideration 13
• Critical issues include problems with wound and anastomosis healing, which could be critical in patients requiring emergency liver transplantation 13

Cardiovascular Monitoring

Monitor for congestive heart failure signs and symptoms throughout bevacizumab therapy. 3

• Bevacizumab increases risk of developing congestive heart failure 3
• Patients should immediately contact healthcare provider for dyspnea, orthopnea, or peripheral edema 3
• Baseline echocardiographic evaluation should be considered in patients with liver vascular malformations, particularly if severe (grade 3-4) 13

Neurological Monitoring

Monitor for posterior reversible encephalopathy syndrome (PRES) with immediate discontinuation required for new onset or worsening neurological symptoms. 3, 8

• PRES presents with headache, seizure, lethargy, confusion, blindness, or altered mental function 8
• Advise patients to immediately contact healthcare provider for new onset or worsening neurological function 3
• PRES is generally reversible with bevacizumab discontinuation and supportive care 8

Infusion-Related Reactions

Monitor patients during and after bevacizumab infusion for hypersensitivity reactions. 3, 8

• Infusion-related reactions are uncommon but can occur 8
• Patients should contact healthcare provider immediately for signs of infusion reactions 3
• Skin rash may occur as an adverse event 8

Common Pitfalls to Avoid

• Do not continue bevacizumab beyond progression: Insufficient data support continuation with second-line regimens after progression on bevacizumab-containing first-line therapy 2
• Do not combine bevacizumab with anti-EGFR antibodies (cetuximab or panitumumab): Combination therapy involving cytotoxics, anti-EGFRs, and anti-VEGFs is not recommended 2
• Do not use maintenance bevacizumab with pemetrexed: This combination has no survival advantage and significantly increased toxicity compared to maintenance pemetrexed or bevacizumab alone 4, 5, 4
• Do not assume blood pressure reduction alone guarantees safety: Close monitoring for all bevacizumab-associated adverse events is required regardless of blood pressure control 14, 8